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Summary In the present studies the effect of bilateral adrenalectomy on the pathophysiologic responses to
recombinant human interleukin-la (rHIL-la) was determined in RIF-I tumour models. Acute vascular injury
and haemorrhagic responses were quantitated by the intra-tumour accumulation of 59Fe radiolabelled erythro-
cytes. In vivo clonogenic tumour cell kill was determined by an excision assay. A single, intraperitoneal
rHIL-la treatment (6.25 x 107 DIO units kg-', 25 fig kg-') resulted in acute tumour haemorrhage and approxi-
mately 55% clonogenic tumour cell kill (24 h). Bilateral adrenalectomy, 24 h before rHIL-la, significantly
increased haemorrhagic responses, but haemodynamic toxicity was severe. This toxicity could be ameliorated
by giving dexamethasone (5 mg kg-') before or up to 3 h after rHIL-la. The effect of dexamethasone on
rHIL-la induced tumour responses in adrenalectomised mice was sequence dependent. Given before rHIL-la,
dexamethasone inhibited tumour haemorrhage. When dexamethasone was given up to 3 h after rHIL-la,
tumour haemorrhage was directly related to sequence interval. Although adrenalectomy and dexamethasone
alone had little effect on RIF-1 tumours, adrenalectomy increased rHIL-la mediated clonogenic tumour cell
kill. The surviving fraction 24 h after rHIL-la (6.25 x 10' D,o units kg-', 25 lsg kg-') and dexamethasone
(5 mg kg-', 2 h after rHIL-la) was 1.3 ± 0.4%. The surviving fraction after this combination in intact mice
(36.7 ± 1.4%) was approximately 30-fold higher than that seen in adrenalectomised mice. The results indicate
that adrenal responses secondary to rHIL-la treatment exert a negative feedback on rHIL-la mediated
responses in solid tumours.
Recombinant human interleukin-lo (rHIL-la) has been
shown to have significant anti-tumour activity in a variety of
experimental tumour models (Nakamura et al., 1986; Nakata
et al., 1988; Braunschweiger et al., 1988) and to be cytotoxic
to some cell lines in vitro (Lachman et al., 1986). Although
rHIL-lo was not toxic to RIF-1 tissue culture cells, this
multifunctional cytokine had significant in vivo anti-tumour
activity (Braunschweiger et al., 1988). In these later studies,
rHIL-la mediated anti-tumour responses were characterised
by reduced tumour blood flow, intravascular congestion, ex-
travascular haemorrhage, oedema, increased vascular
permeability and clonogenic cell kill (Braunschweiger et al.,
1988).
Adrenal hormones are thought to exert a negative feed-
back on the immune responses (del Rey et al., 1984).
Naturally occurring and synthetic corticosteroid hormones
are known to inhibit T cell mitogenesis (Gillis et al., 1979),
natural killer cell (Holbrook et al., Gatti et al., 1986) and
macrophage (Schaffner et al., 1985) function. Increases in
plasma ACTH and corticosterone levels have been observed
within I h after a single rHIL-la treatment (Besedovsky et
al., 1986; del Rey et al., 1987; Morrissey et al., 1988), and it
was postulated that such increases might exert a negative
feedback on rHIL-la stimulated immune responses (del Rey
et al., 1987). The possibility that this feedback pathway could
be exploited, in therapeutic strategies, prompted the present
studies to determine the role of adrenal hormones on rHIL-
lo mediated anti-tumour activity.
Materials and methods
Tumour models
The RIF-1 fibrosarcoma tumour model was maintained ac-
cording to the protocol described by Twentyman et al.
(1980). RIF-1 cells were propagated in RPMI 1640 medium
(Mediatech, Washington DC) supplemented with 10% fetal
bovine serum (FBS) (Irvine Scientific, Santa Ana, CA) and
2 mM glutamine (Gibco, Grand Island, NY), as described
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previously (Braunschweiger et al., 1982; Braunschweiger &
Schiffer, 1986). RIF-1 tumours were routinely produced in
6-10 week old (- 20 g), endotoxin hyposensitive, female
C3H/HeJ mice (Jackson Laboratories, Bar Harbor, ME) by
inoculating 5 x 105 tissue culture cells, subcutaneously, on
the right flank. Studies were initiated 14 days later when
tumours weighed approximately 0.5 g.
Mice were quarantined for 2 weeks before entering studies.
Randomly selected mice were tested and found to be free of
adventitious murine viruses. All mice were housed, 4-5 per
cage, in a temperature and humidity controlled facility with a
12 h light-dark cycle (lights on at 0600 local time) accredited
by the American Association for Accreditation of Laboratory
Animal Care (AAALAC). Mice were provided standard
mouse chow and water ad libitum. All procedures were
reviewed and approved by the Animal Care and Use Com-
mittee of the AMC Cancer Research Center.
Interleukin-la
Recombinant human interleukin-lx was generously provided
by Dr Peter Lomedico (Hoffman-LaRoche, Nutley, NJ). The
rHIL-la used in our studies was highly purified
(2.5 x I09 units mg-1 protein, D1o assay) and essentially free
of endotoxin contamination (<0.125 EU mg-' protein, LAL
assay). rHIL-la was diluted in pyrogen free, sterile 0.9%
NaCI containing 0.05% BSA and administered by intra-
peritoneal injection in 0.2 ml of vehicle. Our standard mouse
dose (6.25 x 107 D1o units kg-'; 25tLg kg-') for these studies
was less than 5% of the LD50 dose for intact mice. This dose
is 2-3 times that shown by Johnson et al. (1989) to stimulate
haematopoiesis sub-optimally in normal mice. Control mice
received vehicle alone as previous studies indicated that heat
inactivated rHIL-lI had no activity at this dose levels. All
rHIL-la and vehicle injections were made at 0800-0900 local
time.
Adrenalectomy
Bilateral adrenalectomy (ADX) was performed, via the dor-
sal route, using Metafane (Pittman-Moore Inc., Washington
Crossing, NJ) anaesthesia, 13 days after tumour inoculation.
rHIL-lo treatments were initiated on day 14. Adrenalec-
tomised mice were given 0.9% NaCl drinking water ad
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libitum. In some experiments, dexamethasone (dexa-
methasone sodium phosphate; ESI Pharmaceuticals Inc.) was
administered as 5 mg kg-' in 0.2 ml sterile, non-pyrogenic
0.9% NaCI by intraperitoneal injection.
Quantitative end-points
The haemorrhagic response in RIF-I tumours after rHIL-lo
was quantitated by determining the tumour packed erythro-
cyte volume using a 59Fe-RBC dilution method described
previously (Braunschweiger et al., 1988; Braunschweiger &
Schiffer, 1986). One tCi of 59Fe-citrate (NEN, Boston, MA)
was injected, i.p., 7 days after tumour implantation. Studies
were initiated at least 7 days later to provide adequate time
for labelled erythrocytes to enter circulation and for unincor-
porated 59Fe to be cleared (Alpen & Cranmore. 1959). At
various intervals after rHIL-l1a treatment, peripheral venous
blood was obtained in heparinised haematocrit tubes from
the post-orbital venous plexus and centrifuged. The s9Fe
radioactivity in the packed RBC fraction was determined in a
gamma well counter (Packard Instruments, Downers Grove,
IL) and expressed as a percentage of the injected dose (ID)
per microlitre of packed RBCs (%IDpl-'). After obtaining
the blood sample, the mice were killed by cervical luxation.
The tumours were resected in toto and weighed. The s9Fe
radioactivity was determined, as above, and expressed as the
%ID g-' wet weight. The tissue packed RBC volume (jl g-')
was calculated as described previously (Braunschweiger &
Schiffer, 1986).
Clonogenic cell survival in RIF-1 tumours was assessed by
a modification (Braunschweiger et al., 1982, 1983, 1988) of
the excision clonogenic cell survival assay described originally
by Twentyman et al. (1980), 24h after rHIL-lo treatment.
Control tumour cell yields were routinely 7-14 x 107 trypan
negative cells g'.
Statistical analysi's
Analysis of variance was used to assess overall variation and
the significance of post-treatment responses (Snedecor &
Cochran, 1980). The Newman-Keuls multiple range test was
used to determine the significance between treatment group
means (Zar, 1974). Where appropriate, Student's t test was
also used. A P value of less than, or equal to, 0.05 was
considered adequate justification to reject the null hypothesis.
Results
In C3H/HeJ mice untreated subcutaneous RIF-l tumours of
less than 1 g rarely exhibit surface haemorrhage, skin ulcera-
tions, central or even local necrosis. A single intraperitoneal
rHIL-la (6.25 x 1O' units kg-'; 25 gig kg-') resulted in acute
haemorrhagic responses that were visually obvious within
3-6 h after treatment. Histologically, progressive vascular
congestion (within 1 h) and frank vascular breakdown and
haemorrhage were seen by 4 h after treatment. In ADX mice
a single rHIL-la treatment (6.25 x 10' units kg ';
25 gig kg-') resulted in haemodynamic shock and the death
of 5/5 mice by 12 h after treatment. The haemodynamic
shock and systemic toxicity of rHIL-la in ADX C3H/HeJ
mice was ameliorated by giving dexamethasone (5.0 mg kg-')
within 3 h after rHIL-lx treatment. At 24 h after rHIL-lx
treatment, the haemorrhagic response in RIF-1 tumours in
ADX mice (dexamethasone, 5 mg kg-', 2 h after rHIL-lo)
was qualitatively greater than that seen in intact mice treated
with rHIL-lI alone (Figure 1). This haemorrhagic response
was quantitated by the intra-tumour accumulation of 59Fe-
RBC.
The effect of ADX and dexamethasone on the rHIL-lo
mediated haemorrhagic responses was quantitated by deter-
mining changes in the tumour packed RBC volumes
(Figure 2). Bilateral ADX was performed 24 h before rHIL-
lo, and changes in tumour packed RBC volumes were deter-
mined 6 h after rHIL-lo. This study interval was chosen
Figure 1 Representative RIF-I tumours from intact (la, 2a) and
adrenalectomised mice (lb, 2b) 24 h after 6.25 x 1O' D,Ounits
kg-' rHIL-la (2a, 2b) or vehicle (la, lb). Adrenalectomised mice
were given 5 mg kg-' dexamethasone 2 h after rHIL-la to
emeliorate haemodynamic shock. The adrenalectomised vehicle
control (1b) also received dexamethasone. Tumours were resected
24 h after rHIL-la treatment (48 h after adrenalectomy) and
bisected along the longest axis to reveal the central region of the
tumour. Control RIF-I tumours (la) of this size (0.5 g) rarely
exhibit central necrosis or haemorrhage. In intact mice, rHIL-la
treatment resulted in significant tumour haemorrhage (2a). In
adrenalectomised mice, rHIL-Io mediated haemorrhagic res-
ponses (2b) were always visually more profound than in intact
mice (2a). Magnification is 1.5 x. Bar = 1 cm.
because an equilibrium is seen by 6 h (Braunschweiger et al.,
1988) and, as stated above, haemodynamic toxicity after
rHIL-hla in ADX mice precluded longer study intervals
unless dexamethasone was also administered. Analysis of
variance indicated that treatment group means were not
derived from the same sample population (F = 19.6,
P <0.0001). In these studies, dexamethasone (5 mg kg-')
alone, ADX alone or ADX plus dexamethasone produced no
visual haemorrhage and had no effect on tumour packed
RBC volumes. rHIL-la alone significantly (P <0.05) in-
creased tumour packed RBC volumes in both intact mice and
ADX mice. The 6 h response in ADX mice was significantly
(P <0.05) greater than that seen in intact mice. Dexa-
methasone given to ADX mice, 30 min before rHIL-la,
prevented tumour haemorrhage at 6 h. When dexamethasone
was given after rHIL-la, the magnitude of the tumour
haemorrhage in ADX mice (6 h) was sequence dependent.
The packed RBC volumes, observed when dexamethasone
was given 2 or 3 h after rHIL-lI, were greater than those
seen in intact controls after rHIL-lI alone or after rHIL-lx
and dexamethasone (2 h after rHIL-la). When dexa-
methasone was given to ADX mice before or up to 3 h after
rHIL-la, no mortality was observed for up to 24 h after
treatment. Longer observation periods were not studied.
Figure 3 shows the time dependent changes in packed
RBC volumes for tumours in intact and adrenalectomised
mice treated with rHIL-lo and dexamethasone (5 mg kg ',
2 h after rHIL-li). The haemorrhagic response in RIF-1
tumours in intact mice treated with the rHIL-la, dexa-
methasone combination was not statistically different from
that seen after rHIL-la alone. However, the haemorrhagic
response in tumours from adrenalectomised mice treated with
the combination of rHIL-lI and dexamethasone (2 h after
rHIL-la) was greater, at all study intervals, than that seen
after a similar combination in intact mice. Similar time
course studies in ADX mice treated with rHIL-lI alone
could not be conducted at the same rHIL-li dose level due
to severe haemodynamic toxicity.
Table I shows the results from a representative experiment
to determine the effect of ADX and dexamethasone on
clonogenic cell survival (24 h) in RIF-I tumours. rHIL-lIo
alone resulted in 45% clonogenic cell kill. Although
adrenalectomy had no significant effect on clonogenic cellu-
larity, the combination of rHIL-lI and dexamethasone (2 hREGULATION OF rHIL-la ANTI-TUMOUR ACTIVITY 11
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Figure 2 The effect of adrenalectomy (A), dexamethasone (D) and rHIL-la (6.25 x 10' D1o units kg-') alone and in combination
on packed RBC volumes of the RIF-1 tumours. Adrenalectomy was performed 24 h before rHIL-la and packed RBC volumes
were determined 6 h after rHIL-la. Dexamethasone (5 mg kg-') was given 2 h after rHIL-la in intact mice (IL-la + D), 24 h after
adrenalectomy (A + D), 30 min before rHIL-la (A + D + IL-la) or at 0.5, 1.0, 2.0 or 3.0 h after rHIL-la in adrenalectomised mice.
Each bar represents the mean ± 1 s.d. for six tumours. ANOVA indicated significant treatment effects and the Newman-Keuls
multiple range test indicated that the response to rHIL-la alone in intact mice was significantly different (*) from that seen in all
other groups except those seen in intact mice treated with rHIL-la + D and those in adrenalectomised mice treated with
dexamethasone 30 min or I h after rHIL-la.
after rHIL-la) in adrenalectomised C3H/HeJ mice resulted in
approximately 97% clonogenic cell kill.
Figure 4 shows the results from a total of 26 experiments
with 104 RIF-1 tumours to assess the effects of rHIL-la
alone or in combination with dexamethasone and adrenalect-
omy on RIF-I clonogenic tumour cell survival. Analysis of
variance indicate highly significant treatment effects
(F = 13.4; P <0.0001). The data from eight experiments
indicated a 46.1 ± 4.6% (s.e.m.) surviving fraction after
rHIL-la alone (b) in intact mice. In ADX mice, the
clonogenic cell survival (eight experiments) after rHIL-la and
dexamethasone (5 mg kg-', 2 h after rHIL-la) was
6 12 18
Hours after IL-la
24 30
Figure 3 The time dependent changes in packed RBC volumes
in RIF-1 tumours after rHIL-la (6.25 x 10' D10units kg-') and
dexamethasone (5 mg kg-', 2 h after rHIL-la) in intact mice (@,
n = 13) and in mice adrenalectomised 24 h before the rHIL-la
and dexamethasone treatment (A, n = 6). Also shown are data
for tumours in intact mice treated with IL-lct alone (-, n = 6).
Each symbol is the mean ± 1 s.d.
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Table I The effect of bilateral adrenalectomy (ADX) and
dexamethasone (DEX) on the survival of RIF-1 clonogenic tumour
cells in representative tumours, 24 h after rHIL-la (25fLg kg)
treatmenta
Clonogenic cellsg' Surviving
Treatment x 106 fraction PC
Control 13.8 ± 3.2 (8)b 1.00
rHIL-la 7.6 ± 2.2 (8) 0.55 <0.025
ADX 11.9 ± 3.1 (5) 0.86 n.s.
ADX + rHIL-la + dex 0.44 0.12 (4) 0.03 <0.001
aExcision clonogenic cell survival assays were performed 24 h after
rHIL-la. IL-la was administered 24 h after ADX. Dexamethasone
(5mg kg-') was given 2 h after rHIL-la. Tumour tissue from three
tumours was pooled for each assay.
bCells were plated out in vitro at several dilutions in duplicate.
Mean ± I s.d. (n).
CANOVA and the Newman-Keuls multiple range test.
Figure 4 The effect of rHIL-la (6.25 x 107 D1O units kg-') alone,
or in combination with adrenalectomy and dexamethasone, on
clonogenic cell survival in RIF-I tumours. a, dexamethasone
(5 mg kg-'), two experiments with four tumours; b, rHIL-la
alone, eight experiments with 19 tumours; c, dexamethasone
(5 mg kg-') given 30 min before rHIL-la in intact mice, two
experiments with four tumours; d, dexamethasone (5 mg kg-')
given 2 h after rHIL-la in intact mice, two experiments with four
tumours; e, adrenalectomy alone, three experiments with eight
tumours; f, dexamethasone given 30 min before rHIL-la in
adrenalectomised mice, one experiment with three tumours; g,
dexamethasone given 2 h after rHIL-la in adrenalectomised mice,
six experiments with 14 tumours. Clonogenic cell survival assays
was determined by excision 24 h after rHIL-la or dexamethasone
treatment. In each experiment, treated and control tumours were
concurrently studied. Tumour tissue from two to three mice was
pooled for clonogenic assays in each experiment. Each bar
represents the mean ± I s.e. *Significantly (P <0.05) different
from rHIL-la alone by ANOVA and the Newman-Keuls multi-
ple range test.
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1.27 ± 0.36% (g). This decreased survival is highly significant
as compared to rHIL-lx alone (P <0.0005) or the same
combination (d, P <0.002) in intact mice. RIF-1 clonogenic
cellularity after dexamethasone (a) or adrenalectomy alone
(e) was significantly greater than that seen after rHIL-lix in
intact mice (b). In intact mice, rHIL-lx and dexamethasone
(2 h after rHIL-la, d) produced a surviving fraction
(36.7 ± 1.4%) consistent with the additive effects of rHIL-lX
and dexamethasone alone. When dexamethasone was given
30 min before rHIL-lDx, clonogenic cell survival in ADX (f)
and intact (c) were similar. Our results suggest that the
post-rHIL-lx adrenal response not only protects the host
from haemodynamic toxicity but also inhibits anti-tumour
responses mediated by rHIL-ax.
Discussion
Our data suggest that adrenal hormones play a major role in
controlling rHIL-la mediated toxicity and anti-tumour
activity. Although prior ADX greatly increased haemorrhagic
responses in tumours after rHIL-la, haemodynamic toxicity
was severe. Recent studies indicated that dexamethasone
treatment before rHIL-la or TNF could ameliorate the
haemodynamic toxicity of these cytokines in adrenalecto-
mised CD-1 mice (Bertini et al., 1988). We have not only
confirmed these findings in the C3H/HeJ mouse, but also
demonstrated that dexamethasone up to 3 h after rHIL-la
prevented toxic deaths. Dexamethasone given before rHIL-lX
not only prevented haemodynamic toxicity in ADX mice, but
also inhibited rHIL-IoE induced haemorrhagic responses in
RIF-1 tumours. On the other hand, when dexamethasone
was given after rHIL-la, haemorrhagic responses increased
as the sequence interval increased, up to 3 h.
Adrenalectomy not only enhanced rHIL-lx mediated vas-
cular responses, but also increased clonogenic tumour cell kill
after rHIL-la. In intact mice, rHIL-la alone and rHIL-la
plus dexamethasone resulted in 46% and 36% surviving
fractions, respectively. We previously showed that although
dexamethasone may have profound anti-proliferative effects
in RIF-1 tumours (Braunschweiger et al., 1982, 1983;
Braunschweiger & Schiffer, 1986), dose levels much higher
than those used here produced little tumour cell kill (Braun-
schweiger et al., 1982). In the present studies, the surviving
fraction after a single 5 mg kg-' dexamethasone treatment
was 78%. Since the additive effects of the dexamethasone
and rHIL-lx treatments would be expected to yield approxi-
mately 35% survival, the observed 1.27% surviving fraction
for RIF-1 tumours in adrenalectomised mice treated with
rHIL-la and dexamethasone (5 mgkg-', 2 h after rHIL-lo;
group g) would indicate that adrenal responses within 2 h
after rHIL-lo have a direct or indirect antagonistic effect on
rHIL-la anti-tumour activity. This is further supported by
the observation that dexamethasone given before rH-IL-la in
ADX mice (group f) inhibited rHIL-lx and mediated
clonogenic cell killing.
In C3H/HeJ mice, plasma ACTH and corticosterone were
increased within 1 h of rHIL-la treatment (Besedovsky et al.,
1986; del Rey et al., 1987; Morrissey et al., 1988). Corti-
costeroids are known to inhibit immune functions (Gillis et
al., 1979; Holbrook et al., 1983; Gatti et al., 1986; Schaffner,
1985) and corticosteroid associated immunoregulation has
been proposed as a homeostatic surveillance mechanism for
the control of immune cell function (del Rey et al., 1984,
1987). While this might explain the enhanced rHIL-la anti-
tumour responses in adrenalectomised mice, other
mechanisms could be operative. rHIL-la is known to pro-
mote the adherence of leukocytes to endothelial cells
(Bevilacqua et al., 1985). Since rHIL-la can stimulate
leukocytes to release proteolytic enzymes and hydrogen
peroxide (Ozaki et al., 1987) such responses could contribute
to rHIL-la mediated tumour vascular injuries. Further,
specific high affinity glucocorticoid receptors have been dem-
onstrated in cultured endothelial cells (Lewis et al., 1986),
and corticosteroids inhibit neutrophil (Ebert & Barclay,
1952), granulocyte (MacGregor, 1976) and lymphoid cell
(Maca et al., 1978) adherence to the endothelium.
rHIL-la is also known to stimulate plasminogen activator
inhibitor (Nachman et al., 1986), procoagulant activity
(Bevilacqua et al., 1983) and arachidonic acid metabolism
(Bernheim, 1986; Besedovsky et al., 1975; Dinarello et al.,
1983). Prostaglandins (PG) E2 and 12 are potent vasodilators
which can increase capillary permeability (Kuehl & Egan,
1980; Issekutz & Movat, 1983). Lipooxygenase metabolites
are also vasoactive (Letts & Cirino, 1985), increase vascular
permeability and promote granulocyte adherence (Samuels-
son, 1983). Corticosteroids are well known inhibitors of PG
and leukotriene synthesis. The concentration of hydrocorti-
sone needed to produce near maximal inhibition of endo-
thelial cell PG synthesis in vitro (Lewis et al., 1986) was
similar to the corticosterone concentrations measured in the
sera of mice after rHIL-la treatment (Besedovsky et al.,
1986; del Rey et al., 1987). These findings might indicate an
important role for vasoactive arachidonic acid metabolites in
the rHIL-lI induced ischaemia and clonogenic cell kill in
RIF-1 tumours.
The responses to rHIL-la in RIF-1 tumours are not unlike
those seen in tumours treated with tumour necrosis factor
(Watanabe et al., 1988; Havell et al., 1988). rHIL-la and
TNF may have similar activities (Bevilaque et al., 1983)
and/or be synergistic (Last-Barney et al., 1988; Ruggiero &
Baglioni, 1987). Further, the regulation of rHIL-la and TNF
production by monocytes and macrophages may be closely
interrelated (Philip & Epstein, 1986), and recent evidence
suggests that these cytokines may be intimately involved in
local macrophage mediated remodelling of tissue extracellular
matrix (Vlassara et al., 1988). Although it is tempting to
postulate a role for TNF in rHIL-loc mediated tumour res-
ponses, there is as yet no direct evidence, aside from similar
pathophysiologies, to support the attractive hypothesis that
TNF may be a local mediator of rHIL-la responses in RIF-1
tumours.
Since the profound vascular injury which characterised
rHIL-la responses in RIF-1 tumours was not seen in muscle
and skin of intact (Braunschweiger et al., 1988) or adrenalec-
tomised hosts, the differences between tumour and normal
tissue vascular structure, function and/or regulation leading
to rHIL-la induced tumour vascular injury might provide a
focus for the development of new therapeutic strategies.
Studies, currently underway, to investigate the negative feed-
back by adrenal hormones on rHIL-lI mediated tumour and
host cell responses could lead to new approaches to enhance
the anti-tumour activity of this multifunctional cytokine. In
this regard, agents which transiently block adrenal steroid
hormone synthesis (e.g. ketoconazole) potentiate rHIL-la
anti-tumour activity (Braunschweiger et al., 1989) without
attendant increases in toxicity.
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